208 related articles for article (PubMed ID: 33548633)
21. Acetoxymethyl Ester of Tetrabromobenzimidazole-Peptoid Conjugate for Inhibition of Protein Kinase CK2 in Living Cells.
Viht K; Saaver S; Vahter J; Enkvist E; Lavogina D; Sinijärv H; Raidaru G; Guerra B; Issinger OG; Uri A
Bioconjug Chem; 2015 Dec; 26(12):2324-35. PubMed ID: 26559659
[TBL] [Abstract][Full Text] [Related]
22. CK2 inhibitor CX4945 induces sequential inactivation of proteins in the signaling pathways related with cell migration and suppresses metastasis of A549 human lung cancer cells.
Ku MJ; Park JW; Ryu BJ; Son YJ; Kim SH; Lee SY
Bioorg Med Chem Lett; 2013 Oct; 23(20):5609-13. PubMed ID: 24012124
[TBL] [Abstract][Full Text] [Related]
23. Protein kinase CK2: a newcomer in the 'druggable kinome'.
Pagano MA; Cesaro L; Meggio F; Pinna LA
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1303-6. PubMed ID: 17073807
[TBL] [Abstract][Full Text] [Related]
24. Functional proteomics strategy for validation of protein kinase inhibitors reveals new targets for a TBB-derived inhibitor of protein kinase CK2.
Gyenis L; Kuś A; Bretner M; Litchfield DW
J Proteomics; 2013 Apr; 81():70-9. PubMed ID: 23017496
[TBL] [Abstract][Full Text] [Related]
25. Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2.
Gyenis L; Turowec JP; Bretner M; Litchfield DW
Biochim Biophys Acta; 2013 Jul; 1834(7):1352-8. PubMed ID: 23416530
[TBL] [Abstract][Full Text] [Related]
26. The selectivity of inhibitors of protein kinase CK2: an update.
Pagano MA; Bain J; Kazimierczuk Z; Sarno S; Ruzzene M; Di Maira G; Elliott M; Orzeszko A; Cozza G; Meggio F; Pinna LA
Biochem J; 2008 Nov; 415(3):353-65. PubMed ID: 18588507
[TBL] [Abstract][Full Text] [Related]
27. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
[TBL] [Abstract][Full Text] [Related]
28. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
Chen F; Huang X; Wu M; Gou S; Hu W
Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
[TBL] [Abstract][Full Text] [Related]
29. Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification.
Sun H; Xu X; Wu X; Zhang X; Liu F; Jia J; Guo X; Huang J; Jiang Z; Feng T; Chu H; Zhou Y; Zhang S; Liu Z; You Q
J Chem Inf Model; 2013 Aug; 53(8):2093-102. PubMed ID: 23937544
[TBL] [Abstract][Full Text] [Related]
30. Development of a potent and selective chemical probe for the pleiotropic kinase CK2.
Wells CI; Drewry DH; Pickett JE; Tjaden A; Krämer A; Müller S; Gyenis L; Menyhart D; Litchfield DW; Knapp S; Axtman AD
Cell Chem Biol; 2021 Apr; 28(4):546-558.e10. PubMed ID: 33484635
[TBL] [Abstract][Full Text] [Related]
31. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and significance of the commonest phosphorylated motifs in the human proteome: a global analysis.
Cesaro L; Pinna LA
Cell Mol Life Sci; 2020 Dec; 77(24):5281-5298. PubMed ID: 32052090
[TBL] [Abstract][Full Text] [Related]
33. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
Battistutta R; Cozza G; Pierre F; Papinutto E; Lolli G; Sarno S; O'Brien SE; Siddiqui-Jain A; Haddach M; Anderes K; Ryckman DM; Meggio F; Pinna LA
Biochemistry; 2011 Oct; 50(39):8478-88. PubMed ID: 21870818
[TBL] [Abstract][Full Text] [Related]
34. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
[TBL] [Abstract][Full Text] [Related]
35. Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor.
Krämer A; Kurz CG; Berger BT; Celik IE; Tjaden A; Greco FA; Knapp S; Hanke T
Eur J Med Chem; 2020 Dec; 208():112770. PubMed ID: 32883634
[TBL] [Abstract][Full Text] [Related]
36. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
[TBL] [Abstract][Full Text] [Related]
37. Structural basis for the design of bisubstrate inhibitors of protein kinase CK2 provided by complex structures with the substrate-competitive inhibitor heparin.
Schnitzler A; Niefind K
Eur J Med Chem; 2021 Mar; 214():113223. PubMed ID: 33571828
[TBL] [Abstract][Full Text] [Related]
38. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
[TBL] [Abstract][Full Text] [Related]
39. The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation.
Cozza G; Venerando A; Sarno S; Pinna LA
Biomed Res Int; 2015; 2015():734127. PubMed ID: 26558278
[TBL] [Abstract][Full Text] [Related]
40. Protein kinase CK2 inhibitors: emerging anticancer therapeutic agents?
Bortolato A; Cozza G; Moro S
Anticancer Agents Med Chem; 2008 Oct; 8(7):798-806. PubMed ID: 18855581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]